Systemic Lupus Erythematosus

The Systemic Lupus Erythematosus pipeline: 59 tracked drugs, 4 approved for this indication.

4 approved / phase 45 Phase 314 Phase 26 Phase 1/226 Phase 14 preclinical / unstaged

Compare the share prices of listed companies in Systemic Lupus Erythematosus →

Total attributable cost

$1.8B

$8,920/patient

Drug spend

Not yet sourced

How this is calculated ↗

All adult and pediatric SLE; 2018 population estimate · US

The Systemic Lupus Erythematosus pipeline

Key trial results for every approved and late-stage drug: Systemic Lupus Erythematosus results by drug.

← all assets